Table 1.
Clinical conditions of the patients at admission (Group 1: Early treatment with FPV and HQ, Group 2: Late treatment with FPV and HQ, Group 3: Treatment with only HQ)
| Group 1 | Group 2 | Group 3 | p-value | |
|---|---|---|---|---|
| Symptoms before admission to hospital (mean [SD] days) | 4.73 (2.447) | 3.73(2.141) | 2.667 (2.628) | NS |
| Drugs use | ||||
| Anti-hypertensive | 20 (41.7%) | 17 (35.4%) | 20 (41.7%) | NS |
| Anti-diabetic | 19 (39.6%) | 13 (27.1%) | 14 (29.2%) | NS |
| Symptoms in admission to hospital | ||||
| Fatigue | 25(52.1%) | 35(72.9%) | 22 (45.8%) | NS |
| Fever | 19 (39.5) | 7 (%14.5) | 7 (%14.5) | NS |
| Cough | 30(62.5%) | 39 (81.2%) | 20 (41.7%) | NS |
| Shortness of breath | 28 (58.3%) | 24 (50.0%) | 6 (12.5%) | NS |
| Nasal congestion | 2 (4.2%) | 2 (4.2%) | 1 (2.1%) | NS |
| Sore throat | 9 (18.8%) | 10 (20.8%) | 8 (16.7%) | NS |
| Nausea and vomiting | 4 (8.3%) | 13 (27.1%)a | 5 (10.4%)a | 0.020a |
| Headache | 16b (33.3%) | 19c (39.6%) | 4b,c (8.3%) |
0.001b 0.001c |
| Anosmia | 4(8.3%) | 1(2.1%) | 0 (0.0%) | NS |
| Diarrhea | 5(10.4%) | 6 (12.5%) | 5 (10.4%) | NS |
| FPV received after symptoms onset (mean [SD] days) | 4.73(2.447) | 8.60 (3.654) | < 0.001 | |
Statistically significant values are presented in bold. Superscript letters define the significant p-values of pairwise comparisons.
FPV Favipiravir; NS: non-significant
a denotes the comparison of patients with nausea and vomiting in Group 2 vs. Group 3
b denotes the comparison of patients with headache in Group 1 vs. Group 3
c denotes the comparison of patients with headache in Group 2 vs. Group 3